BioForum – Our Mental Health Epidemic: The Need for Innovation in Treatment
August 4 @ 4:00 pm – 5:30 pm AEST
This event will be available to attend in-person and virtually. In-person guests are invited to stay on for networking from 5:30-6:30pm. Read more about our COVIDSafe Practices below.
ABOUT THE EVENT
Despite an ever-increasing number of Australians experiencing debilitating mental illnesses, there has been little innovation in mental health treatment options over the last 5 decades.
With a new approach desperately needed, attention is now being paid to the potential role of psychedelic medicines as aides to psychotherapy for a wide array of conditions, including depression, anxiety, post-traumatic stress disorder and addiction. The Australian Government has recently demonstrated its support of these breakthrough therapies with a $15 million grant to kick start clinical trials.
This keynote session will discuss the science and data around psychedelic medicines and the exciting work that is currently being done in this space. We will examine the evidence for psychedelic-assisted therapy, investigate its potential applications, and learn about pre-clinical research and animal models currently being developed in Victoria. You will also learn about how the current policy and regulatory environment affects the work.
Date (AEST): Wednesday 4 August 2021
4:00pm – 5:30pm Presentations and Panel Discussion
5:30pm – 6:30pm Networking (in person guests only)
Venue: Swinburne Studio, ACMI. Federation Square, Melbourne, VIC, 3000
Live stream: Zoom Webinar. A link to join the event will be shared via a confirmation email 24-48hrs prior to the event.
Phone: +61 3 9667 8181
Cancellation Policy (In Person):
Full refund given up to 7 days prior to the event.
No refunds within 7 days of the event.
In the event of postponement due to Government restrictions, registrations will be carried forward to a new date. Should the event be cancelled, or you are unable to attend on the rescheduled date, a full refund will be made available.
Cancellation Policy (Virtual):
Full refund given up to 3 days prior to the event.
No refunds within 3 days of the event.
This event is sponsored by the State Government of Victoria, DJPR.
Our COVID-Safe Practices
In line with current COVID-19 restrictions in Victoria and ACMI’s COVID-Safe plan, in-person ticket allocation for this event is limited and adheres to the current Government restrictions applied to indoor event spaces.
To keep BioMelbourne Network events safe for our members and the greater Victorian community, this event will include measures such as physical distancing, QR code check-in and enhanced hygiene and sanitation processes. Further details will be made available to registered guests via our event webpage and final confirmation email.
Guests Attending In-Person
Each attendee is asked to do a symptom self-assessment prior to leaving home. We ask that you DO NOT attend this event in-person if you are feeling unwell, have any symptoms of COVID-19, are awaiting results of a COVID-19 test or are required to self-isolate or quarantine at the time of the event. Symptoms of COVID-19 include cough, fever, sore throat, fatigue and shortness of breath. If you cannot attend in-person for these reasons, you may receive a full refund or partial refund plus virtual ticket.
We ask that all in-person attendees act in a considerate and respectful manner towards our speakers, fellow guests, ACMI staff and BioMelbourne Network staff:
On arrival, all guests must scan in via the QR codes displayed at the venue entrance.
Maintain adequate physical distance between yourself and others, where possible.
Refrain from unnecessary physical contact, such as hand shaking.
Minimise movement by staying within your allocated spaces or seats, where practical.
Observe all COVID-Safe signage and practices at the venue.
Adhere to requirements for face covering, observe cough etiquette and personal hygiene measures.
Masks are currently mandatory in all public indoor spaces in Victoria. Should restrictions change, registered guests will be notified.
Tania de Jong AM
LL.B (Hons), GradDipMus
Co-founder Mind Medicine Australia, Founder Creative Universe, Creativity Australia, The Song Room & Creative Innovation Global
Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities including Creative Universe, Creativity Australia and With One Voice, Creative Innovation Global, Mind Medicine Australia, Dimension5, MTA Entertainment & Events, Pot-Pourri and The Song Room.
She works across the public, private, creative and community sectors and is passionate about mental health, innovation, diversity and inclusion. Tania speaks and sings around the world as a soloist and with her group Pot-Pourri releasing twelve albums. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global.
She was appointed a Member of the Order of Australia in June 2008. Tania was named in the 100 Women of Influence, the 100 Australian Most Influential Entrepreneurs and named as one of the 100 most influential people in psychedelics globally in 2021. Tania’s TED Talk ‘How Singing Together Changes The Brain’ has sparked international interest. Tania’s mission is to change the world, one voice at a time!
Peter Hunt AM
Founder & Chair of Mind Medicine Australia
As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter was a member of the Advisory Panel of ASIC and chaired the Vincent Fairfax Family Office.
Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. He is Chairman of Mind Medicine Australia which he established with his wife, Tania de Jong, in 2018. He founded Women’s Community Shelter in 2011 and remains on the Board. He was previously Chairman of So They Can, Grameen Australia and Grameen Australia Philippines. Peter is a Director of Project Rozana and an Advisory Board member of the Monash Sustainable Development Institute. Peter also acts as a pro bono adviser to Creativity Australia.
Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.
Dr Paul MacLeman
MBA, BVSC, GRAD DIP ENG (TECH MGT), GRAD CERT ENG (PROCESS DESIGN), GAIDC
Paul has over 25 years’ experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Paul has expertise in capital raising, business development, technology commercialisation, and sales and marketing globally.
He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Paul has previously served as Chairman and/or CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies. Paul is also current Executive Chairman of Isla Pharmaceuticals Inc. and is a Chairman of AdAlta Limited and Non-Executive Director of Sypharma Pty Limited. Paul serves on a number of NFP and government advisory roles.
Professor Arthur Christopoulos
Professor of Analytical Pharmacology, a molecular Neuropsychopharmacologist, and Dean of the Faculty of Pharmacy & Pharmaceutical Sciences
Arthur Christopoulos is Professor of Analytical Pharmacology, a molecular neuropsychopharmacologist, and Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, Monash University Parkville (#1 Faculty in Australia; #2 in the world – Pharmacy & Pharmacology; QS World Rankings, 2021). Prior to his appointment as Dean, he was a Senior Principal Research Fellow of the NHMRC. His research focuses on novel paradigms of drug action at G protein-coupled receptors (GPCRs), the largest drug-target class for current medicines. His innovative research crosses academic and industry boundaries, incorporating computational and mathematical modelling, structural and chemical biology, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease. His research has been applied to fundamental and translational studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes and chronic pain, to name a few, and he has received substantial, long-term support from international and national competitive (e.g., NIH; NHMRC; ARC), charitable (e.g., Wellcome Trust) and commercial (e.g., Servier, GSK, Pfizer, Amgen, Eli Lilly) sources.
Professor Christopoulos has published over 320 publications, including in leading journals such as Nature, Science, Cell, Nature Chemical Biology, PNAS and Nature Communications, and delivered over 180 invited presentations. He has served on the Editorial Board of 8 international journals, consults for numerous companies, (including most major pharma and many biotech) and is a Councillor of the International Union of Basic and Clinical Pharmacology (IUPHAR). He has also been the recipient of multiple awards, including the John J. Abel Award from the American Society for Pharmacology and Experimental Therapeutics, the Rand Medal from the Australian Society of Clinical and Experimental Pharmacologists and Toxicologists, the British Pharmacological Society (BPS) Gaddum Memorial Award, the IUPHAR Analytical Pharmacology Lecturer, the GSK Award for Research Excellence and a Doctor of Laws from the University of Athens. Since